NFKB1 and neoplasm: In a follow up study stromal-mediated resistance was found to involve NF-κB-dependent cFLIP expression that could be prevented by the proteasome inhibitor bortezomib that restored TRAIL sensitivity in tumor cells without affecting stromal HS5 cells (81).